Sareum Holdings (SAR) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 Nov 2022 11:05 AM
RNS
Second Price Monitoring Extn
09 Nov 2022 11:00 AM
RNS
Price Monitoring Extension
09 Nov 2022 09:05 AM
RNS
Second Price Monitoring Extn
09 Nov 2022 09:00 AM
RNS
Price Monitoring Extension
08 Nov 2022 05:23 PM
RNS
Update on SDC-1801 CTA Application
24 Oct 2022 07:00 AM
RNS
Final Results for the Year Ended 30 June 2022
12 Oct 2022 07:00 AM
RNS
Update on SRA737
30 Sep 2022 04:41 PM
RNS
Second Price Monitoring Extn
30 Sep 2022 04:36 PM
RNS
Price Monitoring Extension
12 Sep 2022 07:00 AM
RNS
Sareum notes FDA approval of first TYK2 Inhibitor
28 Jul 2022 07:00 AM
RNS
CTA application to MHRA and Corporate Update
04 Jul 2022 07:00 AM
RNS
Sareum notes GSK's completed acquisition of Sierra
26 Apr 2022 07:00 AM
RNS
Sareum to Present at BioTrinity 2022 Conference
13 Apr 2022 04:00 PM
RNS
Sareum notes acquisition of Sierra Oncology by GSK
13 Apr 2022 11:05 AM
RNS
Second Price Monitoring Extn
13 Apr 2022 11:00 AM
RNS
Price Monitoring Extension
11 Apr 2022 07:00 AM
RNS
European Patent Granted for Sareum's SDC-1802
08 Apr 2022 04:41 PM
RNS
Second Price Monitoring Extn
08 Apr 2022 04:36 PM
RNS
Price Monitoring Extension
06 Apr 2022 02:06 PM
RNS
Second Price Monitoring Extn
06 Apr 2022 02:00 PM
RNS
Price Monitoring Extension
16 Mar 2022 07:00 AM
RNS
SDC-1801: Preclinical Toxicology Report Received
09 Mar 2022 11:06 AM
RNS
Second Price Monitoring Extn
09 Mar 2022 11:00 AM
RNS
Price Monitoring Extension
28 Feb 2022 03:50 PM
RNS
Results of EGM
21 Feb 2022 07:00 AM
RNS
Half-year Report
14 Feb 2022 02:06 PM
RNS
Second Price Monitoring Extn
14 Feb 2022 02:01 PM
RNS
Price Monitoring Extension
04 Feb 2022 07:00 AM
RNS
Publication of Circular; Notice of General Meeting
28 Jan 2022 08:11 AM
RNS
Correction - Issue of Warrants
28 Jan 2022 07:00 AM
RNS
Issue of Warrants
25 Jan 2022 07:00 AM
RNS
Sareum to Participate in Edison Open House Event
17 Dec 2021 07:00 AM
RNS
Subscription to raise £1.63m to progress SDC-1801
16 Dec 2021 04:21 PM
RNS
Result of AGM
16 Dec 2021 07:00 AM
RNS
AGM Statement
15 Dec 2021 07:00 AM
RNS
Intention to grant notice - EU patent for SDC-1802
07 Dec 2021 07:00 AM
RNS
AGM Update
23 Nov 2021 12:57 PM
RNS
Director/PDMR Shareholding
19 Nov 2021 07:00 AM
RNS
Notice of AGM
03 Nov 2021 03:00 PM
RNS
Exercise of Share Options and Director Dealings
29 Oct 2021 07:00 AM
RNS
Appointment of Joint Corporate Broker
25 Oct 2021 07:00 AM
RNS
Sareum: Final Results for Year Ended 30 June 2021
21 Oct 2021 08:32 AM
RNS
Correction - Notice of Results
21 Oct 2021 07:00 AM
RNS
Notice of Results and Investor Presentation
07 Oct 2021 10:42 AM
RNS
US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
29 Sep 2021 10:46 AM
RNS
Reference to SRA737 Timeline at Cantor Conference
19 Aug 2021 07:00 AM
RNS
Trading Statement
09 Aug 2021 01:26 PM
RNS
Subscription to raise £1,000,000
06 Aug 2021 07:19 AM
RNS
SRA737 update
30 Jul 2021 07:00 AM
RNS
US Patent Notice of Allowance for SDC-1802

Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.

The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.

It listed on AIM in 2004 under the ticker SAR.

UK 100